System xCT inhibitors [706] synergize with anti‐PD1 therapy by reversing T cell exhaustion in “cold” tumors [707], whereas GPX4 degraders eliminate apoptosis‐resistant mesenchymal cancer stem cells [708]. Here, GPX4 is linked to cancer.